Dominik Hrabos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dominik Hrabos has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Kateřina Menšíková
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
4 shared publications - Petr Kaňovský
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
4 shared publications Annie Lannuzel
Départment de Neurologie, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-á-Pitre, France
2 shared publications- Carlo Colosimo
LUM University, “F. Miulli” Regional Hospital, 70021 Acquaviva delle Fonti, Italy
2 shared publications - Dorota Šebelová
Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, 77900, Czech Republic.
2 shared publications Gerhard Ransmayr
Department of Neurology, Faculty of Medicine, Johannes Kepler University, Linz, Austria
2 shared publications
Latest Publications
- 30 May 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 151 (1)
GRP78 associates with alpha-synuclein in vulnerable neurons of the Parkinson’s disease brain
- 30 May 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 151 (1)
GRP78 associates with alpha-synuclein in vulnerable neurons of the Parkinson’s disease brain
- Open Access
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Correction: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Open AccessCorrection: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- Open Access
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Open AccessCutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.
- Open Access
- 29 May 2025
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 51 (3) , e70024
Multiplex Immunofluorescent Analysis of Alpha‐Synuclein in Nigral Lewy Bodies With Heat‐Induced Antibody Stripping Reveals an Intricate Multilayered Structure
In the study, we employ an affordable, tissue-saving, and precise simultaneous multiplex immunofluorescence method with heat-induced antibody stripping to identify and structurally analyse nigral Lewy bodies in dopaminergic neurones. Analysis of different alpha-synuclein epitopes and proteoforms reveals an almost uniform, onion-like morphology of the Lewy bodies. The N-terminal and C-terminal domains are predominantly accessible to antibody binding in the peripheral shell of the bodies.
- 29 May 2025
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 51 (3) , e70024
Open AccessMultiplex Immunofluorescent Analysis of Alpha‐Synuclein in Nigral Lewy Bodies With Heat‐Induced Antibody Stripping Reveals an Intricate Multilayered Structure
In the study, we employ an affordable, tissue-saving, and precise simultaneous multiplex immunofluorescence method with heat-induced antibody stripping to identify and structurally analyse nigral Lewy bodies in dopaminergic neurones. Analysis of different alpha-synuclein epitopes and proteoforms reveals an almost uniform, onion-like morphology of the Lewy bodies. The N-terminal and C-terminal domains are predominantly accessible to antibody binding in the peripheral shell of the bodies.
- Open Access
- 22 July 2024
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 50 (4) , e12999
Unfolded protein response markers Grp78 and eIF2alpha are upregulated with increasing alpha‐synuclein levels in Lewy body disease
Aims: Endoplasmic reticulum stress followed by the unfolded protein response is one of the cellular mechanisms contributing to the progression of α‐synuclein pathology in Parkinson's disease and other Lewy body diseases. We aimed to investigate the activation of endoplasmic reticulum stress and its correlation with α‐synuclein pathology in human post‐mortem brain tissue.Methods: We analysed brain tissue from 45 subjects—14 symptomatic patients with Lewy body disease, 19 subjects with incidental Lewy body disease, and 12 healthy controls. The analysed brain regions included the medulla, pons, midbrain, striatum, amygdala and entorhinal, temporal, frontal and occipital cortex. We analysed activation of endoplasmic reticulum stress via levels of the unfolded protein response‐related proteins (Grp78, eIF2α) and endoplasmic reticulum stress‐regulating neurotrophic factors (MANF, CDNF).Results: We showed that regional levels of two endoplasmic reticulum‐localised neurotrophic factors, MANF and CDNF, did not change in response to accumulating α‐synuclein pathology. The concentration of MANF negatively correlated with age in specific regions. eIF2α was upregulated in the striatum of Lewy body disease patients and correlated with increased α‐synuclein levels. We found the upregulation of chaperone Grp78 in the amygdala and nigral dopaminergic neurons of Lewy body disease patients. Grp78 levels in the amygdala strongly correlated with soluble α‐synuclein levels.Conclusions: Our data suggest a strong but regionally specific change in Grp78 and eIF2α levels, which positively correlates with soluble α‐synuclein levels. Additionally, MANF levels decreased in dopaminergic neurons in the substantia nigra. Our research suggests that endoplasmic reticulum stress activation is not associated with Lewy pathology but rather with soluble α‐synuclein concentration and disease progression.
- 22 July 2024
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 50 (4) , e12999
Open AccessUnfolded protein response markers Grp78 and eIF2alpha are upregulated with increasing alpha‐synuclein levels in Lewy body disease
Aims: Endoplasmic reticulum stress followed by the unfolded protein response is one of the cellular mechanisms contributing to the progression of α‐synuclein pathology in Parkinson's disease and other Lewy body diseases. We aimed to investigate the activation of endoplasmic reticulum stress and its correlation with α‐synuclein pathology in human post‐mortem brain tissue.Methods: We analysed brain tissue from 45 subjects—14 symptomatic patients with Lewy body disease, 19 subjects with incidental Lewy body disease, and 12 healthy controls. The analysed brain regions included the medulla, pons, midbrain, striatum, amygdala and entorhinal, temporal, frontal and occipital cortex. We analysed activation of endoplasmic reticulum stress via levels of the unfolded protein response‐related proteins (Grp78, eIF2α) and endoplasmic reticulum stress‐regulating neurotrophic factors (MANF, CDNF).Results: We showed that regional levels of two endoplasmic reticulum‐localised neurotrophic factors, MANF and CDNF, did not change in response to accumulating α‐synuclein pathology. The concentration of MANF negatively correlated with age in specific regions. eIF2α was upregulated in the striatum of Lewy body disease patients and correlated with increased α‐synuclein levels. We found the upregulation of chaperone Grp78 in the amygdala and nigral dopaminergic neurons of Lewy body disease patients. Grp78 levels in the amygdala strongly correlated with soluble α‐synuclein levels.Conclusions: Our data suggest a strong but regionally specific change in Grp78 and eIF2α levels, which positively correlates with soluble α‐synuclein levels. Additionally, MANF levels decreased in dopaminergic neurons in the substantia nigra. Our research suggests that endoplasmic reticulum stress activation is not associated with Lewy pathology but rather with soluble α‐synuclein concentration and disease progression.
- Open Access
- 31 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3916
Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma
PD-L1 is one of the two programmed cell death 1 (PD-1) ligands and a part of an immune checkpoint system (PD-1/PD-L1) with widespread clinical application. The aim of this study was to investigate PD-L1 expression and its association with clinicopathological and prognostic significance in non-clear cell renal cell carcinoma (non-ccRCC) patients. A total of 41 papillary (pRCC) and 20 chromophobe (chRCC) RCC tumors were examined for PD-L1 expression by immunohistochemistry in the cancer cells and tumor-infiltrating mononuclear cells (TIMCs). PD-L1 positivity was detected in 36.6% pRCC and 85.0% chRCC cancer cells, while PD-L1 positivity was observed in 73.2% pRCC and 50.0% chRCC TIMCs. PD-L1 positivity in both pRCC and chRCC tumor cells was not correlated with any of the examined clinicopathological features, while PD-L1 positivity in TIMCs was associated with the age of patients with pRCC. During follow-up, the death was documented among 6 patients with pRCC. Papillary RCC patients with PD-L1-positive tumor cells were significantly associated with an increased risk of death compared with patients with PD-L1-negative cancer cells. A similar trend was observed when comparing PD-L1 expression in TIMCs. However, no differences in overall survival for PD-L1-positive pRCC patients with compared to PD-L1-negative patients were observed in tumor cells or TIMCs.
- 31 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3916
Open AccessAssociation between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma
PD-L1 is one of the two programmed cell death 1 (PD-1) ligands and a part of an immune checkpoint system (PD-1/PD-L1) with widespread clinical application. The aim of this study was to investigate PD-L1 expression and its association with clinicopathological and prognostic significance in non-clear cell renal cell carcinoma (non-ccRCC) patients. A total of 41 papillary (pRCC) and 20 chromophobe (chRCC) RCC tumors were examined for PD-L1 expression by immunohistochemistry in the cancer cells and tumor-infiltrating mononuclear cells (TIMCs). PD-L1 positivity was detected in 36.6% pRCC and 85.0% chRCC cancer cells, while PD-L1 positivity was observed in 73.2% pRCC and 50.0% chRCC TIMCs. PD-L1 positivity in both pRCC and chRCC tumor cells was not correlated with any of the examined clinicopathological features, while PD-L1 positivity in TIMCs was associated with the age of patients with pRCC. During follow-up, the death was documented among 6 patients with pRCC. Papillary RCC patients with PD-L1-positive tumor cells were significantly associated with an increased risk of death compared with patients with PD-L1-negative cancer cells. A similar trend was observed when comparing PD-L1 expression in TIMCs. However, no differences in overall survival for PD-L1-positive pRCC patients with compared to PD-L1-negative patients were observed in tumor cells or TIMCs.
- 9 February 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (3) , 195-196
Reply to: Questioning the cycad theory of Kii ALS–PDC causation
- 9 February 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (3) , 195-196
Reply to: Questioning the cycad theory of Kii ALS–PDC causation
- 8 September 2023
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (10) , 599-616
Endemic parkinsonism: clusters, biology and clinical features
The term ‘endemic parkinsonism’ refers to diseases that manifest with a dominant parkinsonian syndrome, which can be typical or atypical, and are present only in a particular geographically defined location or population. Ten phenotypes of endemic parkinsonism are currently known: three in the Western Pacific region; two in the Asian-Oceanic region; one in the Caribbean islands of Guadeloupe and Martinique; and four in Europe. Some of these disease entities seem to be disappearing over time and therefore are probably triggered by unique environmental factors. By contrast, other types persist because they are exclusively genetically determined. Given the geographical clustering and potential overlap in biological and clinical features of these exceptionally interesting diseases, this Review provides a historical reference text and offers current perspectives on each of the 10 phenotypes of endemic parkinsonism. Knowledge obtained from the study of these disease entities supports the hypothesis that both genetic and environmental factors contribute to the development of neurodegenerative diseases, not only in endemic parkinsonism but also in general. At the same time, this understanding suggests useful directions for further research in this area.
- 8 September 2023
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (10) , 599-616
Endemic parkinsonism: clusters, biology and clinical features
The term ‘endemic parkinsonism’ refers to diseases that manifest with a dominant parkinsonian syndrome, which can be typical or atypical, and are present only in a particular geographically defined location or population. Ten phenotypes of endemic parkinsonism are currently known: three in the Western Pacific region; two in the Asian-Oceanic region; one in the Caribbean islands of Guadeloupe and Martinique; and four in Europe. Some of these disease entities seem to be disappearing over time and therefore are probably triggered by unique environmental factors. By contrast, other types persist because they are exclusively genetically determined. Given the geographical clustering and potential overlap in biological and clinical features of these exceptionally interesting diseases, this Review provides a historical reference text and offers current perspectives on each of the 10 phenotypes of endemic parkinsonism. Knowledge obtained from the study of these disease entities supports the hypothesis that both genetic and environmental factors contribute to the development of neurodegenerative diseases, not only in endemic parkinsonism but also in general. At the same time, this understanding suggests useful directions for further research in this area.